Could this ASX healthcare share surge on COVID-19 testing?

Sonic Healthcare Limited (ASX: SHL) shares could surge on the back of a recent contract win from the Australian Government to test for COVID-19.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Testing for the COVID-19 pandemic is an important step in re-opening the Australian economy. The Sonic Healthcare Limited (ASX: SHL) share price could be poised to surge higher in 2020 after the company was recently awarded a contract from the Australian Government to test for COVID-19.  

What contract has Sonic won?

Last week, Sonic Healthcare informed the market that the company had been awarded a contract from the Australian Government to provide rapid sample collection and testing for COVID-19 in residential aged care facilities.

With elderly Australians being the highest priority, approximately 2,700 aged care facilities across the country will be eligible for the service. Sonic will provide testing through its national network of laboratories and collection teams.

Sonic Healthcare's laboratories in New South Wales and Queensland were the first in Australia to perform high-volume COVID-19 testing during the early stages of the pandemic. According to management, Sonic's laboratories have processed almost 20% of all COVID-19 tests in Australia.

Sonic has collectively tested more than 100,000 Australians for COVID-19 and is poised to roll out additional testing platforms across the country.

How has Sonic performed in the pandemic?

Sonic is the third-largest pathology provider in the world, generating revenue from radiology and pathology services. Despite being initially sold down heavily, the Sonic share price has bounced back more than 30% from its low in mid-March.

In late March, Sonic Healthcare informed the market it was withdrawing its earnings guidance for FY20 due to the uncertainty of the CVOID-19 pandemic. The company reached the decision after social isolation and quarantine measures impacted normal diagnostic volumes as patients opted to delay routine testing.

In addition to playing a crucial frontline role, Sonic assured shareholders that the company remained in a strong financial position with a balance sheet boasting almost $1 billion in cash on hand.

Should you buy?

Sonic Healthcare has a history of fuelling growth through acquisitions and winning new contracts. In addition to the contract win from the Australian Government, Sonic has also partnered with philanthropic organisation Minderoo Foundation to increase testing capacity for COVID-19.

If testing proves a successful measure in aged care facilities, the company could be in line for a wider range of contract wins. With the COVID-19 pandemic still an evolving situation, I think Sonic Healthcare's contract win could have great potential in the short and medium-term.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »